- ￥550 - 950
- MedChemExpress(MCE)
- 美国
- HY-B0008
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
MK-231
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
38194-50-2
- 规格：
10 mM * 1 mL/100 mg/500 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥605.0 |
|---|---|---|---|
| 规格： | 100 mg | 产品价格： | ￥550.0 |
| 规格： | 500 mg | 产品价格： | ￥950.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Sulindac
CAS No. : 38194-50-2
MCE 国际站：Sulindac
产品活性：Sulindac (MK-231) 是一种口服活性非甾体类抗炎药。Sulindac 也是一种免疫调节剂。Sulindac 可用于脊柱关节炎、痛风性关节炎及多种癌症如结直肠癌、肺癌的研究。
研究领域：NF-κB | Immunology/Inflammation
作用靶点：NF-κB | PD-1/PD-L1
In Vitro: Sulindac (MK-231) (500 μM, 48 h) is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors.
Sulindac (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells.
Sulindac (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac and SIRT1 upregulation promoted TGF-β1-induced EMT.
In Vivo: Sulindac (MK-231) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume and increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy.
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P.
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy.
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | NF-κB Signaling Compound Library | Stem Cell Signaling Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Small Molecule Immuno-Oncology Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Antioxidant Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Pyroptosis Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Transcription Factor-Targeted Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Antidepressant Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Cancer Stem Cells Compound Library | Pain-Related Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Mitochondrial Toxicity Compound Library | Phorbol 12-myristate 13-acetate | Bortezomib | BAY 11-7082 | TAK-243 | JSH-23 | Sulfasalazine | Shikonin | Atezolizumab | Pyrrolidinedithiocarbamate ammonium | Triptolide | Aspirin | Pembrolizumab | Dihydroartemisinin | Cilengitide | BMS-1 | Baicalin | Nivolumab | Parthenolide | BMS-202 | BAY 11-7085 | 5-Aminosalicylic Acid | CBL0137 hydrochloride | Rocaglamide | JQ-1 (carboxylic acid) | Betulinic acid | Isoginkgetin | Durvalumab | Tomivosertib | SN50 | SC75741
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验人员、精神失常、溃疡病、癫痫、帕金森病及肾病患者。 舒林酸 舒林酸（sulindac，苏林大）的作用及应用均似吲哚美辛，但强度不及后者的一半；其特点是作用较持久，不良反应也较少。 甲芬那酸、氯芬那酸和双氯芬酸 甲芬那酸（mefenamic acid,甲灭酸）、氯芬那酸（clofenamic acid,氯灭酸）和双氯芬酸（diclofenac）均为邻氨苯甲酸（芬那酸）的衍生物。它们都能抑制PG合成酶而具有抗炎、解热及镇痛作用。 与其他解热
。本药抑制PG合成酶作用强大。“阿司匹林哮喘”者禁用本药，因此可发生哮喘。 本药禁用于孕妇、儿童、机械操作人员、精神失常、溃疡病、癫痫、帕金森病及肾病患者。 舒林酸 舒林酸（sulindac，苏林大）的作用及应用均似吲哚美辛，但强度不及后者的一半；其特点是作用较持久，不良反应也较少。 甲芬那酸、氯芬那酸和双氯芬酸 甲芬那酸（mefenamic acid,甲灭酸）、氯芬那酸（clofenamic acid,氯灭酸）和双氯芬酸（diclofenac）均
氨基酚（paracetamol）0.5g/次，3次/日。 保泰松（phenylbutazone） 0.1～0.2g/次,3次/日。症状改善后改为1次/日。 羟基保泰松（oxyphenbutazone）0.1g/次,3次/日。餐中服，一周后递减，0.1～0.2g/日。 吲哚美辛（indomethacin）25mg/次，2～3次/日。餐中服，以后每周可递增25mg至每日总量为100～150mg。 舒林酸（sulindac）150～200mg/次，2次/日。每日最大剂量400mg。
技术资料暂无技术资料 索取技术资料
